Besides treatment resistance through epitope loss of CD19, BCP-ALL cells, mainly KTM2A—rearranged leukemia, can escape CD19-targeted therapy via lineage switch towards an AML-like phenotype [112,113,114]. This evidence concerns the gene CD19 and leukemia.